MicroRNA-150 Functions As a Tumor Suppressor and Sensitizes Osteosarcoma to Doxorubicin-induced Apoptosis by Targeting RUNX2

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2020 Jan 4

PMID 31897096

Citations 6

Authors

Zhonghua Ling

Gentao Fan

Danhua Yao

Jianning Zhao

Yinhua Zhou

Jinzhu Feng

Guangxin Zhou

Yong Chen

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma (OS) is the most common form of bone malignancy in children and adolescents. MicroRNAs (miRNAs) have been associated with the development and progression of OS. In the present study, reverse transcription-quantitative PCR, western blotting, Cell Counting Kit-8, luciferase and Transwell assays were performed to investigate the biological function of microRNA-150 (miR-150) in OS. The results revealed that miR-150 was significantly downregulated in OS cell lines (HOS, SAOS2, MG-63 and U2OS) in comparison with the normal osteoblast cells (hFOB1.19). Overexpression of miR-150 significantly inhibited cell proliferation in OS cells. miR-150 could sensitize OS cells to chemotherapy treatment of doxorubicin. Runt-related transcription factor 2 (RUNX2) was identified as a target gene of miR-150. RUNX2 knockdown exhibited similar inhibitory effects on both OS cell proliferation and chemotherapy sensitivity. Restoration of RUNX2 reversed the biological function of miR-150. Finally, miR-150 overexpression and RUNX2 knockdown enhanced caspase-3 cleavage. Taken together, the present study established a novel molecular mechanism, in that miR-150 plays tumor suppressor and chemoprotective roles by targeting RUNX2 in OS, indicating that miR-150 may be a potential therapeutic target for OS therapy in the future.

Citing Articles

The Role of MicroRNAs in the Pathogenesis of Doxorubicin-Induced Vascular Remodeling.

Podyacheva E, Snezhkova J, Onopchenko A, Dyachuk V, Toropova Y Int J Mol Sci. 2025; 25(24.

PMID: 39769102 PMC: 11728060. DOI: 10.3390/ijms252413335.

MicroRNA Expression in Patients with Coronary Artery Disease and Hypertension-A Systematic Review.

Kondracki B, Kloda M, Jusiak-Kloda A, Kondracka A, Wacinski J, Wacinski P Int J Mol Sci. 2024; 25(12).

PMID: 38928136 PMC: 11204345. DOI: 10.3390/ijms25126430.

Tumor Suppressor MicroRNAs in Clinical and Preclinical Trials for Neurological Disorders.

Lui A, Do T, Alzayat O, Yu N, Phyu S, Santuya H Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675388 PMC: 11054060. DOI: 10.3390/ph17040426.

Decreased MicroRNA-150 Exacerbates Neuronal Apoptosis in the Diabetic Retina.

Yu F, Ko M, Ko G Biomedicines. 2021; 9(9).

PMID: 34572320 PMC: 8469350. DOI: 10.3390/biomedicines9091135.

Torki Z, Ghavi D, Hashemi S, Rahmati Y, Rahmanpour D, Pornour M Cancer Chemother Pharmacol. 2021; 88(5):771-793.

PMID: 34510251 DOI: 10.1007/s00280-021-04337-8.

References

Olfa G, Christophe C, Philippe L, Romain S, Khaled H, Pierre H . RUNX2 regulates the effects of TNFalpha on proliferation and apoptosis in SaOs-2 cells. Bone. 2010; 46(4):901-10. DOI: 10.1016/j.bone.2009.12.027. View

Wang T, Ji F, Dai Z, Xie Y, Yuan D . Increased expression of microRNA-191 as a potential serum biomarker for diagnosis and prognosis in human osteosarcoma. Cancer Biomark. 2015; 15(5):543-50. DOI: 10.3233/CBM-150493. View

Villadsen S, Bramsen J, Ostenfeld M, Wiklund E, Fristrup N, Gao S . The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer. 2011; 106(2):366-74. PMC: 3261682. DOI: 10.1038/bjc.2011.520. View

Dreyer F, Baur A . Biogenesis and Functions of Exosomes and Extracellular Vesicles. Methods Mol Biol. 2016; 1448:201-16. DOI: 10.1007/978-1-4939-3753-0_15. View

Lee D, Qi J, Bradner J, Said J, Doan N, Forscher C . Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. Int J Cancer. 2014; 136(9):2055-64. PMC: 4824295. DOI: 10.1002/ijc.29269. View

Pereira B, Zhou Y, Gupta A, Leong D, Aung K, Ling L . Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1). J Cell Physiol. 2009; 221(3):778-88. PMC: 2768260. DOI: 10.1002/jcp.21921. View

Jin M, Shi C, Yang C, Liu J, Huang G . Upregulated circRNA ARHGAP10 Predicts an Unfavorable Prognosis in NSCLC through Regulation of the miR-150-5p/GLUT-1 Axis. Mol Ther Nucleic Acids. 2019; 18:219-231. PMC: 6796700. DOI: 10.1016/j.omtn.2019.08.016. View

Bacci G, Briccoli A, Rocca M, Ferrari S, Donati D, Longhi A . Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 2003; 14(7):1126-34. DOI: 10.1093/annonc/mdg286. View

Li C, Yu T, Qiu H, Zhao X, Zhou C, Qi C . miR-150 is downregulated in osteosarcoma and suppresses cell proliferation, migration and invasion by targeting ROCK1. Oncol Lett. 2017; 13(4):2191-2197. PMC: 5403695. DOI: 10.3892/ol.2017.5709. View

10.

Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G . Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006; 32(6):423-36. DOI: 10.1016/j.ctrv.2006.05.005. View

11.

Wang L, Aireti A, Aihaiti A, Li K . Expression of microRNA-150 and its Target Gene IGF2BP1 in Human Osteosarcoma and their Clinical Implications. Pathol Oncol Res. 2018; 25(2):527-533. PMC: 6449306. DOI: 10.1007/s12253-018-0454-0. View

12.

Ghali O, Chauveau C, Hardouin P, Broux O, Devedjian J . TNF-alpha's effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression. J Bone Miner Res. 2010; 25(7):1616-26. DOI: 10.1002/jbmr.52. View

13.

Jones K, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo G . miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 2012; 72(7):1865-77. PMC: 3328547. DOI: 10.1158/0008-5472.CAN-11-2663. View

14.

Rainusso N, Wang L, Yustein J . The adolescent and young adult with cancer: state of the art -- bone tumors. Curr Oncol Rep. 2013; 15(4):296-307. DOI: 10.1007/s11912-013-0321-9. View

15.

Forrester M, Seth D, Hausladen A, Eyler C, Foster M, Matsumoto A . Thioredoxin-interacting protein (Txnip) is a feedback regulator of S-nitrosylation. J Biol Chem. 2009; 284(52):36160-36166. PMC: 2794731. DOI: 10.1074/jbc.M109.057729. View

16.

Gorlick R, Khanna C . Osteosarcoma. J Bone Miner Res. 2010; 25(4):683-91. DOI: 10.1002/jbmr.77. View

17.

Tang M, Lin L, Cai H, Tang J, Zhou Z . MicroRNA-145 downregulation associates with advanced tumor progression and poor prognosis in patients suffering osteosarcoma. Onco Targets Ther. 2013; 6:833-8. PMC: 3712084. DOI: 10.2147/OTT.S40080. View

18.

Wang D, Qiu C, Zhang H, Wang J, Cui Q, Yin Y . Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets. PLoS One. 2010; 5(9). PMC: 2948010. DOI: 10.1371/journal.pone.0013067. View

19.

Esquela-Kerscher A, Slack F . Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-69. DOI: 10.1038/nrc1840. View

20.

Muoio D . TXNIP links redox circuitry to glucose control. Cell Metab. 2007; 5(6):412-4. DOI: 10.1016/j.cmet.2007.05.011. View